Baseline patients and disease characteristics compared according to study group
| . | 1st CR (N = 68) . | P value . | 2nd CR (N = 31) . | P value . | R/R (N = 16) . |
|---|---|---|---|---|---|
| Patient characteristics | |||||
| Age, y, median (range) | 42 (17-84) | .91 | 39 (16-77) | .95 | 30 (20-76) |
| Sex (female), n (%) | 31/68 (46) | .19 | 19/31 (61) | .07 | 5/16 (31) |
| Baseline disease characteristics | |||||
| WBC (× 109/L), median (range) | 17.5 (1-730) | .09 | 9 (1-325) | .23 | 24 (1-600) |
| Pro-B phenotype, n (%) | 14/68 (21) | .15 | 4/31 (13) | .99 | 2/16 (17) |
| BCR::ABL1, n (%) | 16/68 (24) | .15 | 12/31 (39) | .004 | 0/16 (0) |
| KMT2A-r, n(%) | 10/60 (17) | .09 | 1/31 (7) | .03 | 3/9 (21) |
| IKZF1del, n(%) | 22/55 (40) | .81 | 10/28 (35) | .39 | 1/8 (13) |
| CNS disease, n (%) | 8/68 (12) | .27 | 1/31 (3) | .10 | 3/15 (20) |
| Non-CNS EM disease, n (%) | 15/68 (22) | .99 | 6/31 (19) | .71 | 4/15 (27) |
| Blin indications, n (%) | |||||
| CR, MRD+ | 56/68 (82) | / | N/A | / | N/A |
| CR, MRD– | 9/68 (13) | / | N/A | / | N/A |
| Refractory disease | N/A | / | N/A | / | 2/16 (13) |
| Relapse | N/A | / | 31/31 (100) | .11 | 14/16 (87) |
| Pre-blin therapies, n (%) | |||||
| Allo-HCT | 1/68 (1) | .23 | 2/31 (6) | .04 | 5/16 (31) |
| CAR T cells | 0/68 (0) | / | 0/68 (0) | .34 | 1/16 (6) |
| Inotuzumab ozogamicin | 5/68 (7) | .27 | 5/31 (16) | .65 | 1/16 (6) |
| Blin therapy | |||||
| No. of cycles, median (range) | 2 (1-6) | .24 | 2 (1-6) | .35 | 2 (1-4) |
| . | 1st CR (N = 68) . | P value . | 2nd CR (N = 31) . | P value . | R/R (N = 16) . |
|---|---|---|---|---|---|
| Patient characteristics | |||||
| Age, y, median (range) | 42 (17-84) | .91 | 39 (16-77) | .95 | 30 (20-76) |
| Sex (female), n (%) | 31/68 (46) | .19 | 19/31 (61) | .07 | 5/16 (31) |
| Baseline disease characteristics | |||||
| WBC (× 109/L), median (range) | 17.5 (1-730) | .09 | 9 (1-325) | .23 | 24 (1-600) |
| Pro-B phenotype, n (%) | 14/68 (21) | .15 | 4/31 (13) | .99 | 2/16 (17) |
| BCR::ABL1, n (%) | 16/68 (24) | .15 | 12/31 (39) | .004 | 0/16 (0) |
| KMT2A-r, n(%) | 10/60 (17) | .09 | 1/31 (7) | .03 | 3/9 (21) |
| IKZF1del, n(%) | 22/55 (40) | .81 | 10/28 (35) | .39 | 1/8 (13) |
| CNS disease, n (%) | 8/68 (12) | .27 | 1/31 (3) | .10 | 3/15 (20) |
| Non-CNS EM disease, n (%) | 15/68 (22) | .99 | 6/31 (19) | .71 | 4/15 (27) |
| Blin indications, n (%) | |||||
| CR, MRD+ | 56/68 (82) | / | N/A | / | N/A |
| CR, MRD– | 9/68 (13) | / | N/A | / | N/A |
| Refractory disease | N/A | / | N/A | / | 2/16 (13) |
| Relapse | N/A | / | 31/31 (100) | .11 | 14/16 (87) |
| Pre-blin therapies, n (%) | |||||
| Allo-HCT | 1/68 (1) | .23 | 2/31 (6) | .04 | 5/16 (31) |
| CAR T cells | 0/68 (0) | / | 0/68 (0) | .34 | 1/16 (6) |
| Inotuzumab ozogamicin | 5/68 (7) | .27 | 5/31 (16) | .65 | 1/16 (6) |
| Blin therapy | |||||
| No. of cycles, median (range) | 2 (1-6) | .24 | 2 (1-6) | .35 | 2 (1-4) |
blin, blinatumomab; CAR, chimeric antigen receptor; CNS, central nervous system; EM, extramedullary; MRD+, any detectable MRD; WBC, white blood cells.